X4 Pharmaceuticals
Clinical trials sponsored by X4 Pharmaceuticals, explained in plain language.
A biopharmaceutical company focused on developing therapies for rare immune system diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to boost immune cells in rare blood disorder Results expected Sep 2027 (estimated) 🚀 Make-or-break
-
Experimental drug aims to boost immunity in rare WHIM syndrome
Disease control CompletedThis phase 3 trial tests whether mavorixafor can raise neutrophil levels in people with WHIM syndrome, a rare genetic condition that weakens the immune system. Participants receive either mavorixafor or a placebo to see if the drug helps maintain infection-fighting white blood ce…
Phase 3 • Sponsor: X4 Pharmaceuticals • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Liver function may change how mavorixafor works in the body
Knowledge-focused CompletedThis study investigates how a single dose of mavorixafor is processed in people with mild to moderate liver impairment compared to healthy volunteers with normal liver function. Researchers will measure drug levels in the blood and monitor safety and tolerability. The goal is to …
Phase 1 • Sponsor: X4 Pharmaceuticals • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC